Claims
- 1. A pharmaceutical composition for lowering lipid-peroxide levels comprising an effective amount of a therapeutic agent in admixture with a pharmaceutically acceptable carrier or diluent, wherein the therapeutic agent is selected from the group consisting of compounds of formula (I): ##STR11## in which: R.sup.1 represents a hydrogen atom, an alkyl group, a substituted alkyl group, a C.sub.2 -C.sub.6 alkenyl group, a C.sub.6 -C.sub.10 carbocyclic aryl group, a substituted C.sub.6 -C.sub.10 carbocyclic aryl group or an alkoxycarbonyl group wherein the alkoxy part has from 1 to 6 carbon atoms, said substituents on said alkyl and aryl groups being selected from the group consisting of:
- halogen atoms, hydroxy groups, C.sub.1 -C.sub.7 aliphatic acyloxy groups, C.sub.6 -C.sub.10 carbocyclic aryl carboxylic acyloxy groups, .alpha.-alkoxyalkoxy groups where both alkoxy parts have from 1 to 6 carbon atoms, a tetrahydro-2-furanyloxy- or tetrahydro-2-pyranyloxy group, trialkylsilyloxy groups where each alkly part has from 1 to 6 carbon atoms, aralkyloxy groups where the aryl part is C.sub.6 -C.sub.10 carbocyclic aryl and the alkyl part is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy groups, C.sub.1 -C.sub.6 aminoalkoxy groups, alkylaminoalkoxy groups where the alkyl and alkoxy parts both have from 1 to 6 carbon atoms, dialkylaminoalkoxy groups where the alkyl and alkoxy parts all have from 1 to 6 carbon atoms, carboxy groups, alkoxycarbonyl groups where the alkoxy part has from 1 to 6 carbon atoms, carbamoyl groups, alkylcarbamoyl groups where the alkyl part has from 1 to 6 carbon atoms, dialkylcarbamoyl groups where both alkyl parts have from 1 to 6 carbon atoms and, as substituents on aryl groups only, C.sub.1 -C.sub.6 alkyl groups;
- R.sup.2 represents a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or a C.sub.3 or C.sub.4 alkenyl group;
- R.sup.3 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;
- R.sup.4 represents a hydroxy group, a C.sub.1 -C.sub.21 aliphatic acyloxy group or a C.sub.6 -C.sub.10 carbocyclic aryl carboxylic acyloxy group;
- R.sup.5 represents a C.sub.1 -C.sub.12 alkyl group, a C.sub.1 -C.sub.6 alkoxy group, a hydroxy group, a C.sub.1 -C.sub.7 aliphatic acyloxy group or a C.sub.6 -C.sub.10 carbocyclic aryl carboxylic acyloxy group;
- R.sup.6 represents a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or a C.sub.1 -C.sub.6 alkoxy group; and
- n is 0, 1, or 2;
- and pharmaceutically acceptable salts thereof.
- 2. A composition as claimed in claim 1, wherein:
- R.sup.1 represents a hydrogen atom, a C.sub.1 -C.sub.10 alkyl group, a C.sub.1 -C.sub.10 alkyl group having from 1 to 3 substituents selected from the group consisting of halogen atoms, hydroxy groups, alkoxycarbonyl groups wherein the alkoxy part has from 1 to 6 carbon atoms, C.sub.1 -C.sub.7 aliphatic acyloxy groups, aryl acyloxy groups, .alpha.-alkoxyalkoxy groups wherein both alkoxy parts have from 1 to 6 carbon atoms, groups, trialkylsilyloxy groups wherein each alkyl part has from 1 to 6 carbon atoms, aralkyloxy groups wherein the aryl part is C.sub.6 -C.sub.10 carbocyclic aryl and the alkyl part is C.sub.1 -C.sub.6 alkyl and carboxy groups, a C.sub.2 -C.sub.6 alkenyl group, a phenyl group or a phenyl group having from 1 to 3 substituents selected from the group consisting of C.sub.1 -C.sub.6 alkyl groups, halogen atoms, hydroxy groups, C.sub.1 -C.sub.7 aliphatic acyloxy groups, said aryl acyloxy groups, .alpha.-alkoxyalkoxy groups where each alkoxy part has from 1 to 6 carbon atoms, groups, trialkylsilyloxy groups where each alkyl part has from 1 to 6 atoms and aralkyloxy groups where the aryl part is C.sub.6 -C.sub.10 carbocyclic aryl and the alkyl part is C.sub.1 -C.sub.6 alkyl; and R.sup.2 represents a hydrogen atom.
- 3. A composition as claimed in claim 1, wherein:
- R.sup.3 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group; R.sup.5 represents a C.sub.1 -C.sub.6 alkyl group; and R.sup.6 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group.
- 4. A composition as claimed in claim 3, wherein n is O.
- 5. A composition as claimed in claim 1, wherein n is O.
- 6. A composition as claimed in claim 1, wherein:
- R.sup.1 represents a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkyl group having from 1 to 3 substituents selected from the group consisting of hydroxy groups, C.sub.1 -C.sub.7 aliphatic acyloxy groups and benzoyloxy groups, a phenyl group, or a phenyl group having from 1 to 3 substituents selected from the group consisting of hydroxy groups and C.sub.1 -C.sub.7 aliphatic acyloxy groups; R.sup.2 represents a hydrogen atom; R.sup.3 represents a C.sub.1 -C.sub.6 alkyl group; R.sup.4 represents a hydroxy group, a C.sub.1 -C.sub.7 aliphatic acyloxy group or a benzoyloxy group; R.sup.5 represents a C.sub.1 -C.sub.6 alkyl group; R.sup.6 represents a C.sub.1 -C.sub.6 alkyl group; and n is O.
- 7. A composition as claimed in claim 1, wherein said therapeutic agent is selected from the group consisting of:
- 5-Acetoxy-2,4,6,7-tetramethyl-1,3-benzoxathiole
- 5-Hydroxy-2,4,6,7-tetramethyl-1,3-benzoxathiole
- 2-Ethyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole
- 5-Hydroxy-4,6,7-trimethyl-2-propyl-1,3-benzoxathiole
- 5-Hydroxy-2-isopropyl-4,6,7-trimethyl-1,3-benzoxathiole
- 2-Butyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole
- 2-Hexyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole
- 3-(5-Hydroxy-4,6,7-trimethyl-1,3-benzoxathiole-2-yl)propionic acid
- 5-Hydroxy-4,6,7-trimethyl-2-phenyl-1,3-benzoxathiole
- 5-Hydroxy-2-(o-hydroxyphenyl)-4,6,7-trimethyl-1,3-benzoxathiole
- 5-Hydroxy-4,6,7-trimethyl-1,3-benzoxathiole
- 5-Benzoyloxy-2,4,6,7-tetramethyl-1,3-benzoxathiole
- Methyl 3-(5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole-2-yl)propionate
- 3-(5Hydroxy-4,6,7-trimethyl-1,3-benzoxathiole-2-yl)propanol
- 2-Allyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole
- 5-Acetoxy-4,6,7-trimethyl-2-propyl-1,3-benzoxathiole
- 5-Benzoyloxy-4,6,7-trimethyl-2-propyl-1,3-benzoxathiole
- 6-t-Butyl-5-hydroxy-2-propyl-1,3-benzoxathiole
- 5-Acetoxy-6-t-butyl-2-propyl-1,3-benzoxathiole
- 6-t-Butyl-5-hydroxy-2-methyl-1,3-benzoxathiole
- 5-Acetoxy-6-t-butyl-2-methyl-1,3-benzoxathiole
- 6-t-Butyl-5-butyryloxy-2-methyl-1,3-benzoxathiole
- and 3-(6-t-Butyl-5-hydroxy-1,3-benzoxathiole-2-yl)propanol
- 8. A composition as claimed in claim 1, formulated for oral administration.
- 9. A composition as claimed in claim 1, formulated for parenteral administration.
- 10. A composition as claimed in claim 1, formulated for topical administration.
- 11. A method for lowering lipid-peroxide levels in a mammal by the administration thereto of an effective amount of a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of compounds of formula (I): ##STR12## in which: R.sup.1 represents a hydrogen atom, an alkyl group, a substituted alkyl group, a C.sub.2 -C.sub.6 alkenyl group, a C.sub.6 -C.sub.10 carbocyclic aryl group, a substituted C.sub.6 -C.sub.10 carbocyclic aryl group or an alkoxycarbonyl group wherein the alkoxy part has from 1 to 6 carbon atoms, said substituents on said alkyl and aryl groups being selected from the group consisting of:
- halogen atoms, hydroxy groups, C.sub.1 -C.sub.7 aliphatic acyloxy groups, C.sub.6 -C.sub.10 carbocyclic aryl carboxylic acyloxy groups, .alpha.-alkoxyalkoxy groups where both alkoxy parts have from 1 to 6 carbon atoms, a tetrahydro-2-furanyloxy- or tetrahydro-2-pyranyloxy group, trialkylsilyloxy groups where each alkyl part has from 1 to 6 carbon atoms, aralkyloxy groups where the aryl part is C.sub.6 -C.sub.10 carbocyclic aryl and the alkyl part is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy groups, C.sub.1 -C.sub.6 aminoalkoxy groups, alkylaminoalkoxy groups where the alkyl and alkoxy parts both have from 1 to 6 carbon atoms, dialkylaminoalkoxy groups where the alkyl and alkoxy parts all have from 1 to 6 carbon atoms, carboxy groups, alkoxycarbonyl groups where the alkoxy part has from 1 to 6 carbon atoms, carbamoyl groups, alkylcarbamoyl groups where the alkyl part has from 1 to 6 carbon atoms, dialkylcarbamoyl groups where both alkyl parts have from 1 to 6 carbon atoms and, as substituents on aryl groups only, C.sub.1 -C.sub.6 alkyl groups;
- R.sup.2 represents a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or a C.sub.3 or C.sub.4 alkenyl group;
- R.sup.3 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;
- R.sup.4 represents a hydroxy group, a C.sub.1 -C.sub.21 aliphatic acyloxy group or a C.sub.6 -C.sub.10 carbocyclic acyloxy group;
- R.sup.5 represents a C.sub.1 -C.sub.12 alkyl group, a C.sub.1 -C.sub.6 alkoxy group, a hydroxy group, a C.sub.1 -C.sub.7 aliphatic acyloxy group or a C.sub.6 -C.sub.10 carbocyclic aryl carboxylic acyloxy group;
- R.sup.6 represents a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or a C.sub.1 -C.sub.6 alkoxy group; and
- n is 0, 1, or 2;
- and pharmaceutically acceptable salts thereof.
- 12. A method as claimed in claim 11, wherein:
- R.sup.1 represents a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkyl group having from 1 to 3 substituents selected from the group consisting of hydroxy groups, C.sub.1 -C.sub.7 aliphatic acyloxy groups and benzoyloxy groups, a phenyl group, or a phenyl group having from 1 to 3 substituents selected from the group consisting of hydroxy groups and C.sub.1 -C.sub.7 aliphatic acyloxy groups; R.sup.2 represents a hydrogen atom; R.sup.3 represents a C.sub.1 -C.sub.6 alkyl group; R.sup.4 represents a hydroxy group, a C.sub.1 -C.sub.7 aliphatic acyloxy group or a benzoyloxy group; R.sup.5 represents a C.sub.1 -C.sub.6 alkyl group; R.sup.6 represents a C.sub.1 -C.sub.6 alkyl group; and n is O.
- 13. A method as claimed in claim 11, wherein said therapeutic agent is selected from the group consisting of:
- 5-Hydroxy-2,4,6,7-tetramethyl-1,3-benzoxathiole
- 2-Ethyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole
- 5-Hydroxy-4,6,7-trimethyl-1,3-benzoxathiole
- and
- 3-(5-Hydroxy-4,6,7-trimethyl-1,3-benzoxathiole-2-yl)propanol.
Priority Claims (1)
Number |
Date |
Country |
Kind |
59-60198 |
Mar 1984 |
JPX |
|
Parent Case Info
This application is a continuation of application Ser. No. 036,250 filed Apr. 9, 1987, which is a division of Ser. No. 716,171 filed Mar. 26, 1985 now U.S. Pat. No. 4,691,027.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4572912 |
Yoshioka et al. |
Feb 1986 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
716171 |
Mar 1985 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
36250 |
Apr 1987 |
|